featured
Selumetinib + Adjuvant Radioactive Iodine for High-Risk Differentiated Thyroid Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)
J. Clin. Oncol 2022 Feb 22;[EPub Ahead of Print], AL Ho, M Dedecjus, LJ Wirth, RM Tuttle, WB Inabnet, J Tennvall, F Vaisman, L Bastholt, AG Gianoukakis, P Rodien, R Paschke, R Elisei, D Viola, K So, D Carroll, T Hovey, B Thakre, JA FaginFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.